Last night, Virbac announced Q1 sales of €375.2m, up 8.5% y-o-y. LFL growth was 4.9%.

Stifel believes that this figure is bang in line with its expectations and shows organic growth of +4.9%, i.e. a slight acceleration from +4.1% in Q4 2024 and +3.4% in Q3 2024. Stifel confirms its buy recommendation on the stock, with the same target price of E390.

In his daily report, the analyst emphasizes that this growth rate is in line with the trajectory needed to reach the 2025 growth target (i.e. 4%-6% organic revenue growth).

Europe and Latin America are showing solid growth rates of around +8%, and the Group is off to a good start for the year, while the second half of the year should see a more favorable basis for comparison (the group achieved organic growth of +11% in H1 2024 and +4% in H2 2024), Stifel says.

On the negative side, the analyst notes that Australia is still in sharp decline (-15%), and that momentum is weak in the United States (+2.7%) and Asia (+3.9%).


Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses disseminated by Cercle Finance are only intended to assist investors in their decision-making. Cercle Finance cannot be held directly or indirectly liable as a result of the use of the information and analyses by readers. It is recommended that any uninformed person consult a professional advisor before investing. This indicative information does not in any way constitute an incentive to sell or a solicitation to buy.